Maintenance Rituximab for Patients with Follicular Lymphoma (FL) Responding to Front-Line Induction with Rituximab/Chemotherapy

Maintenance Rituximab for Patients with Follicular Lymphoma (FL) Responding to Front-Line Induction with Rituximab/Chemotherapy

CME test	Downloadable PDF	PowerPoint slides	CME Information and Faculty Disclosures
Read Dr Love's original email (from July 8, 2010)			Subscribe to Dr Love's email alerts

Slides from a presentation at ASCO 2010 and transcribed comments from recent interviews with Stephanie A Gregory, MD (6/18/10), John P Leonard, MD (6/28/10) and Mathias J Rummel, MD, PhD (6/7/10)

Salles GA et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. Proc ASCO 2010;Abstract 8004.

Go to next Journal Club

Go to previous Journal Club